Researchers examined a random sample of health insurance claim records of 16 million patients in the U.S. between 2006 and 2020 for use of semaglutide drugs
People using diabetes drugs such as Ozempic for weight loss are at higher risk of pancreatitis, bowel obstruction and stomach paralysis compared to those who use another medication approved specifically for obesity management, a University of British Columbia study suggests.
The study, published in JAMA, found these adverse gastrointestinal effects happen in non-diabetic patients using the drugs specifically for weight loss.
People using diabetes drugs such as Ozempic for weight loss are at higher risk of pancreatitis, bowel obstruction and stomach paralysis compared to those who use another medication approved specifically for obesity management, a University of British Columbia study suggests.